About Us EPS Innovative Medicine will serve as a
bridge to send
promising seeds from
both Japan and overseas to
the market
as soon as possible.

About Us

EPS Innovative Medicine (Japan) Limited is the core company of the drug discovery and development of the healthcare business operated by EPS Creative Health Technology Group Limited. Our business is to enhance the value of drug candidates and technologies introduced by our joint venture (JV), which is a company of our group, or those found in our research division, by combining the knowledge and know-how accumulated by EPS Group over many years and promoting clinical development on our own. We will then realize the manufacturing and launching in Japan and particularly in China or licensing them to our partner enterprises.
We will build a platform for new drug discovery and regenerative medicine and act as a “bridge” so that promising drug candidates and technologies in Japan and other countries can be delivered early not only in Japan but to the world market, particularly in Asia.

Greetings from the President

Satoshi Okoso

Representative Director
President and Representative Corporate Officer and CEO
Satoshi Okoso

EPS Innovative Medicine (Japan) Limited was founded on October 8, 2021 as the core company of the Drug Discovery and Development of the healthcare business operated by EPS Creative Health Technology Group Limited.
Recently, the environment in the pharmaceutical market in Europe, the U.S., Asia including Japan has been changing dramatically. The global pharmaceutical market continues to expand day by day, and the pharmaceutical market in Asia, including China, is growing at a tremendous pace. Among them, China’s market size reached the same level as Japan’s in 2015 and exceeded Japan in 2018 to become the second largest market in the world. The market is expected to be $170 billion in 2023 and to continue to grow at a high rate.
In addition, if we look at the share of the number of new drugs in the world in recent years, approximately 80% of them have been originated by biotech companies, while conventionally major pharmaceutical companies spent many years in research and development with a large amount of resources. Unfortunately, however, the environment in Japan is not yet supportive of bringing the drug candidates discovered by academic organizations and biotech companies, and it is not easy to develop these candidates into new drug products.
EPS Innovative Medicine (Japan) Limited will not only research and develop drug candidates in-house, but will also acquire licenses to develop and market promising drug candidates from academic organizations and biotech companies, and will utilize the knowledge and know-how accumulated by the EPS Group to deliver new drugs not only to Japan, but also to the ever-growing Chinese market. EPS Innovative Medicine (Japan) Limited is committed to making progress to meet the expectations of patients and families who desire new drugs, as a drug discovery company linking Japan, China, and other Asian countries.

Contact Us

For more information,
please feel free to contact us from below.